Bayer hires Rothschild for spinoff advice; Novartis adds 83 to Diovan job cuts toll;

@FiercePharma: Allergan rebuffed Actavis bid, saying it's 'closing in' on a $10B-plus Salix buy. Story | Follow @FiercePharma

@EricPFierce: Mylan proposes plan to avoid nitroglycerin shortage in Canada. Article via FiercePharmaManufacturing | Follow @EricPFierce

> Bayer tapped Rothschild to advise it on plans to set up its plastics business as a separate company, either via an IPO or a spinoff valued at some $13 billion. Report

> Novartis ($NVS) said it's cutting another 83 jobs at the plant in Suffern, NY, that currently turns out its off-patent blood pressure drug Diovan. Report

> The FDA warned doctors to guard against fake drugs by keeping an eye on unscrupulous drug distributors with "too good to be true" pricing offers. Report

> Biogen Idec ($BIIB) won kudos from the Dow Jones Sustainability World Index for its efforts in labor fairness, environmentally efficient operations and supply chain management. Report

Medical Device News

@FierceMedDev: Treasury's crackdown on inversion could scupper Medtronic-Covidien deal. More | Follow @FierceMedDev

@MichaelGFierce: Vaxxas' nanopatch garners WHO support in search of #polio vax application. Story via FierceDrugDelivery | Follow @MichaelGFierce

@VarunSaxena2: In case you're wondering, $MDT can cancel its deal with $COV without penalty if it's due to changes in the tax code. Wonder what will happen. | Follow @VarunSaxena2

@EmilyWFierce: T2 Biosystems wins FDA approval for sepsis diagnostic system. More | Follow @EmilyWFierce

> Philips splits in two, making HealthTech its sole priority. News

> Ivantis gets $71M for glaucoma device, while Minerva secures $21M to reduce menstrual bleeding. Article

Biotech News

@FierceBiotech: If you missed yesterday's live #Fierce15 announcement, catch the replay from @partnering360. Watch | Follow @FierceBiotech

@JohnCFierce: Fun watching the inversion news bend from "Oh no!" to "Hey, wait a minute" this morning. Maybe not the kiss of death after all? | Follow @JohnCFierce

@DamianFierce: Fierce15 winner Molecular Partners just filed to raise ~$134M in a Swiss IPO. | Follow @DamianFierce

> Fast-tracked Ebola studies put Tekmira, Mapp and Sarepta in the spotlight. News

> Biogen shoulders into gene therapy amid a second honeymoon for the field. More

> NEA pitches in on a $27M gamble on Tracon's mid-stage cancer drug program. Story

> Who loses in biopharma as Treasury moves to block tax inversions? Article

Biotech Research News

> Researchers develop tumor-on-a-chip to test new cancer drugs. Article

> Genetic 'switch' may control aging process. News

> Drug development for tropical diseases gets $15.3M boost. Item

> Pathway discovery reveals another potential Alzheimer's drug target. Article

> New technique generates stem cells at highly efficient rate. Story

Pharma Manufacturing News

> GSK accidentally dumps 'liquid contaminated with poliovirus' into Belgian sewer system. Report

> Ritedose to invest up to $110M in South Carolina plant. Article

> Recall of Mylan nitroglycerin revised to avoid shortage. Story

> GSK influenza plant in Texas on track to start up in 2016. Item

> Merck KGaA deal for Sigma-Aldrich gets it some specialty manufacturing capacity. More

And Finally... The makers of a skin-cancer diagnostics app, Dermofit, are planning for a launch to med students, dermatology nurses and general practitioners. Report

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.